Filing Flows › Recursion Pharmaceuticals (RXRX) › Q3 2026 › vs Q3 2025
Recursion Pharmaceuticals (RXRX) Q3 2026 vs Q3 2025 (year over year)
Recursion Pharmaceuticals's revenue rose $13.4M (+258%) from $5.2M in Q3 2025 to $18.6M in Q3 2026. The biggest changes: Operating revenue +$13.1M (+262%); Grant revenue +$305K (+159%).
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Operating revenue | $18.1M | $5.0M | $13.1M | +262% |
| Grant revenue | $497K | $192K | $305K | +159% |
| Revenue | $18.6M | $5.2M | $13.4M | +258% |
| Other income, net | $4.2M | $10.0M | −$5.8M | -58% |
| Net loss | $119M | $162M | −$43.2M | -27% |
| Costs & expenses | $142M | $177M | −$35.6M | -20% |
| Operating costs | $142M | $177M | −$35.6M | -20% |
| Income tax | $25K | $3K | $22K | +733% |
| Cost of revenue | $10.0M | $14.7M | −$4.6M | -32% |
| Research & development | $99.1M | $121M | −$21.9M | -18% |
| General & admin | $32.6M | $41.6M | −$9.1M | -22% |
| Operating cash sources | $119M | $162M | −$43.2M | -27% |
| Depreciation & amortization | $16.5M | $21.0M | −$4.5M | -21% |
| Share-based compensation | $23.0M | $25.2M | −$2.2M | -9% |
| Working capital & other | $2.1M | −$1.4M | $3.5M | — |
| Cash used in operations | $77.4M | $117M | −$40.0M | -34% |
| Net loss absorbed | $119M | $162M | −$43.2M | -27% |
Questions
How much did Recursion Pharmaceuticals's revenue grow year over year in Q3 2026?
Recursion Pharmaceuticals's revenue rose $13.4M (+258%) from $5.2M in Q3 2025 to $18.6M in Q3 2026.
What drove Recursion Pharmaceuticals's revenue change in Q3 2026?
Operating revenue +$13.1M (+262%); Grant revenue +$305K (+159%).